Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heron Therapeutics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

Recent & Breaking News (NDAQ:HRTX)

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

PR Newswire December 23, 2024

U.S. District Court Upholds Validity of CINVANTI® Patents

PR Newswire December 3, 2024

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire November 12, 2024

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

PR Newswire November 4, 2024

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

PR Newswire October 29, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

PR Newswire October 10, 2024

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire September 25, 2024

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

PR Newswire September 3, 2024

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire August 6, 2024

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

PR Newswire July 30, 2024

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

PR Newswire July 15, 2024

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire July 2, 2024

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire May 29, 2024

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

PR Newswire May 7, 2024

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

PR Newswire April 24, 2024

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

PR Newswire April 11, 2024

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire March 28, 2024

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

PR Newswire March 12, 2024

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

PR Newswire February 28, 2024

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

PR Newswire January 23, 2024